Hudson Bay Capital Management
MDGL icon

Hudson Bay Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Hudson Bay Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,000
Closed -$2.29M – 1402
2025
Q3 		$2.29M Buy
+5,000
New +$1.87M 0.01% 729

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hudson Bay Capital Management's MDGL Position: Q2 2025 in Review

Hudson Bay Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2025, closing a stake of 12,610 shares — an estimated $4.18M sold.

Hudson Bay Capital Management first reported a position in MDGL in Q4 2017 and held it in 4 quarters. The position peaked at $5.26M in Q1 2018. 305 funds tracked by Wall St. Rank hold MDGL as of Q2 2025.

  • Hudson Bay Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Hudson Bay Capital Management sold 12,610 Madrigal Pharmaceuticals shares in Q2 2025, an estimated $4.18M.
  • Hudson Bay Capital Management first reported a position in Madrigal Pharmaceuticals in Q4 2017 and held it in 4 quarters.
  • Hudson Bay Capital Management's Madrigal Pharmaceuticals position peaked at $5.26M in Q1 2018.
  • 305 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2025.

Based on Hudson Bay Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.